Naglazyme (Galsulfase)

Galsulfase is a recombinant form of human N‑acetylgalactosamine‑4‑sulfatase. When administered intravenously, it enters cells and restores the enzymatic activity needed to break down dermatan sulfate within lysosomes, thereby decreasing substrate buildup that causes the clinical manifestations of MPS VI.

The dose of Naglazyme is individualized. A qualified prescriber determines the amount and frequency based on the patient’s body weight, disease severity, and clinical response. Dosing regimens are not standardized and should follow the prescribing information.

Safety of Naglazyme during pregnancy and lactation has not been established. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To order Naglazyme, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Naglazyme is the only approved enzyme replacement therapy specifically for MPS VI. Other lysosomal storage disease therapies target different enzymes or conditions, so Naglazyme remains the standard of care for patients with deficient N‑acetylgalactosamine‑4‑sulfatase activity.

Naglazyme must be stored refrigerated at 2 °C to 8 °C. Keep the vial in its original container, protect it from light, and avoid freezing or shaking. Once reconstituted, the solution should be used promptly according to the prescribing information.

Naglazyme is supplied as a sterile powder for solution for injection. The powder is reconstituted with the appropriate diluent and administered by intravenous infusion under medical supervision, typically in a hospital or specialized infusion center.

The most serious risks include severe or life‑threatening hypersensitivity reactions such as anaphylaxis, significant hepatic enzyme elevation, and rare hematologic abnormalities like thrombocytopenia. Patients should be monitored closely during and after infusion for any signs of these reactions.

Naglazyme is contraindicated in patients with a known severe hypersensitivity to Galsulfase, any component of the formulation, or a history of serious allergic reactions to enzyme replacement therapies. Such individuals should avoid treatment and discuss alternative options with their physician.